Company / SG&A Expense
Larimar Therapeutics, Inc. SG&A Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.2M
FY2019
5-year range
$4.2M / $19.2M
FY2015-FY2019
Trend
-33.5%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $19M to $12M over the past 2 years.
Based on SEC 10-K filings.
$12M in FY2019 with a 5-year CAGR of +40.2%.
Improved from $19M to $12M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +14.3%
- 5-Year CAGR
- +40.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +40.2%, indicating consistent growth.
- In FY2019, sg&a expense decreased 33.5% year-over-year.
- Peak sg&a expense was recorded in FY2017.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $12.2M | -33.5% |
| FY2018 | $18.3M | -4.7% |
| FY2017 | $19.2M | +135.8% |
| FY2016 | $8.1M | +93.0% |
| FY2015 | $4.2M | +87.8% |
| FY2014 | $2.2M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026